### 1 TITLE PAGE

2	
3	Age-Modulated Immuno-Metabolic Proteome Profiles of Deceased Donor
4	<b>Kidneys Predict 12-Month Posttransplant Outcome</b>
5	
6	<b>Authors:</b> Philip D Charles <sup>1,2†</sup> , Sarah Fawaz <sup>3,4*</sup> , Rebecca H Vaughan <sup>3,4*</sup> , Simon Davis <sup>2</sup> , Priyanka
7	Joshi <sup>3</sup> , Iolanda Vendrell <sup>2</sup> , Ka Ho Tam <sup>5</sup> , Roman Fischer <sup>2</sup> , Benedikt M Kessler <sup>2</sup> , Edward J
8	Sharples <sup>6</sup> , Alberto Santos <sup>1,7,8</sup> , Rutger J Ploeg <sup>3,4</sup> , Maria Kaisar <sup>3,4†</sup>
9	
10	Affiliations:
11	<sup>1</sup> Big Data Institute, Nuffield Department of Medicine, University of Oxford; Oxford, United
12	Kingdom.
13	<sup>2</sup> Target Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine,
14	University of Oxford; Oxford, United Kingdom.
15	<sup>3</sup> Research and Development, NHS Blood and Transplant; Bristol & Oxford, United Kingdom.
16	<sup>4</sup> Nuffield Department of Surgical Sciences and Oxford Biomedical Research Centre, University
17	of Oxford; Oxford, United Kingdom.
18	<sup>5</sup> Engineering Department, University of Oxford; United Kingdom.
19	<sup>6</sup> University Hospital Oxford; Oxford, United Kingdom.

- <sup>20</sup> <sup>7</sup>Center for Health Data Science, University of Copenhagen; Copenhagen, Denmark.
- <sup>21</sup> <sup>8</sup>Novo Nordisk Foundation Center for Protein Research, University of Copenhagen;
- 22 Copenhagen, Denmark.
- <sup>23</sup> \*These authors contributed equally.
- 24

25 <sup>†</sup>Corresponding authors. Email: <u>philip.charles@ndm.ox.ac.uk; maria.kaisar@nds.ox.ac.uk</u>

26

### 27 Keywords:

Kidney transplantation, Machine Learning, Data Independent Acquisition, Proteomics, Donor
 age, QUOD

30

### 31 ABSTRACT

32 Organ availability limits kidney transplantation, the best treatment for end-stage kidney 33 disease. Deceased donor acceptance criteria have been relaxed to include older donors with 34 higher risk of inferior posttransplant outcomes. More granular prediction models, based on deeper resolution organ assessment and understanding of damage processes, could substantially 35 improve donor organ allocation and reduce graft dysfunction risk. Here, we profiled pre-36 37 implantation kidney biopsy proteomes from 185 deceased donors by high-resolution mass spectrometry and used machine learning to integrate and model these data, and donor and 38 recipient clinical metadata to predict outcome. Our analysis and orthogonal validation on an 39

40	independent cohort revealed 136 proteins predictive of outcome, 124 proteins of which showed
41	donor-age modulated predictive effects. Observed associations with inflammatory, catabolic,
42	lipid metabolism and apoptotic pathways may predispose donor kidneys to suboptimal
43	posttransplant outcomes. Our work shows that integrating kidney proteome information with
44	clinical metadata enhances the resolution of donor kidney quality stratification, and the
45	highlighted biological mechanisms open new research directions in developing interventions
46	during donor management or preservation to improve kidney transplantation outcome.
47	
48	TRANSLATIONAL STATEMENT
48 49	TRANSLATIONAL STATEMENT We profiled the proteome of pre-implantation biopsies selected from donor kidneys on
48 49 50	TRANSLATIONAL STATEMENT We profiled the proteome of pre-implantation biopsies selected from donor kidneys on the basis of paired 12-month graft function. Our data reveal a signature of proteins which
48 49 50 51	<b>TRANSLATIONAL STATEMENT</b> We profiled the proteome of pre-implantation biopsies selected from donor kidneys on         the basis of paired 12-month graft function. Our data reveal a signature of proteins which         contribute to transplant outcomes, many of these show different strengths of association
48 49 50 51 52	TRANSLATIONAL STATEMENT We profiled the proteome of pre-implantation biopsies selected from donor kidneys on the basis of paired 12-month graft function. Our data reveal a signature of proteins which contribute to transplant outcomes, many of these show different strengths of association dependent on donor age. The biological themes of the identified candidates reinforce immuno-
48 49 50 51 52 53	TRANSLATIONAL STATEMENT We profiled the proteome of pre-implantation biopsies selected from donor kidneys on the basis of paired 12-month graft function. Our data reveal a signature of proteins which contribute to transplant outcomes, many of these show different strengths of association dependent on donor age. The biological themes of the identified candidates reinforce immuno- metabolic and catabolic mechanisms as potential contributors to donor kidney susceptibility that

55

### 56 **INTRODUCTION**

57 Kidney transplantation is the optimal treatment for end-stage kidney disease. Compared 58 to dialysis, transplantation increases life-expectancy, improves quality of life and is cost-59 effective. Limited availability of suitable donor kidneys impedes treatment of chronic kidney 60 disease, and often prolongs dialysis, increasing morbidity and mortality. Deceased donor organ 61 shortages, living donation decline in some countries and emerging ageing populations drive

increased utilization of older deceased donor kidneys, now comprising more than half of offered
 organs<sup>1,2</sup>.

64	Ageing associates with time-dependent decline of organ function, evidenced in kidneys
65	by histologic lesions, such as tubular atrophy, interstitial fibrosis, glomerulosclerosis, and
66	arteriosclerosis. Older kidneys demonstrate fewer functioning glomeruli, less renal mass,
67	podocyte dysfunction, and impaired cellular repair <sup>3</sup> . Glomerular diseases are more common and
68	associated with worse outcomes in older patients <sup>4</sup> . Age accelerates the transition from Acute
69	Kidney Injury (AKI) to chronic injury <sup>5</sup> and is an independent risk factor of graft dysfunction and
70	loss for deceased donor kidneys <sup>6</sup> ; furthermore, older donors are more likely to suffer from
71	additional risk factors such as diabetes, hypertension or cardiovascular disease.

Donor age is incorporated in clinical scoring algorithms to inform kidney allocation decisions<sup>7,8</sup>, but is insufficient to consistently predict transplant outcomes. Current front-line models incorporating further clinical factors such as terminal serum creatinine, history of hypertension and diabetes<sup>8,9</sup> show consistent performance across demographics but lack granular predictive accuracy<sup>10</sup>.

Molecular analyses of biopsies plausibly offer higher resolution assessment of organ state; but require 'big picture' understanding of mechanisms associated specifically with poor outcome, rather than immediate (but potentially recoverable) acute injury. Deceased donors are frequently assessed as having sustained damage (i.e. AKI) based on serum creatinine levels<sup>14</sup>, however this metric poorly associates with longer term outcomes<sup>13–16</sup>.

Mass spectrometry (MS) proteomic studies can provide such a 'big picture', but have heretofore lacked cohort capacity to represent demographic diversity<sup>17</sup>. Advances in highthroughput techniques<sup>18</sup> now allow sensitivity and depth without sacrificing throughput capacity.

85	Developments in machine learning and nonlinear regression analyses furthermore offer tools to
86	extract maximal knowledge from limited size experimental cohorts, with applications in disease
87	staging, disease recurrence prediction, treatment response monitoring, and biomarker
88	identification <sup>19,20</sup> .
89	Integration of deep proteomic profiles with heterogenous clinical and demographic
90	factors using modern statistical tools can empower the next steps toward precision medicine <sup>21</sup> .
91	Here, we benefit from the granularity provided by our MS-based proteomic profiling to report
92	age- and immunometabolism-related proteomic signatures in pre-implantation kidney biopsies
93	associated with transplant outcomes.

94

#### 95 **METHODS**

### 96 Study Design

Deceased donor pre-transplantation kidney biopsies (n=186; 1 sample excluded during
data processing) were obtained from the Quality in Organ Donor (QUOD) biobank, a national
multi-center UK wide bioresource of deceased donor clinical samples acquired during donor
management and organ procurement. Biopsies were obtained from Donation after Brain Death
(DBD) donors and Donation after Circulatory Death (DCD) donors at the back table immediately
after kidney procurement.

103 Selection of biopsies was based on paired 12-month post-transplant outcomes. To 104 minimize the impact of recipient factors, we only included kidneys for which the contralateral 105 kidney was transplanted with similar outcome. Kidneys were selected to cover the outcome 106 continuum i.e. the range of estimated Glomerular Filtration Rate (eGFR) in the recipient at 12

107	months posttransplant, from primary non-function to eGFR>80 ml/min/1.73 m <sup>2</sup> , excluding
108	extreme demographic or clinical factors where possible. Samples were linked to corresponding
109	donor and recipient demographic and clinical metadata, provided by NHS Blood and Transplant
110	National Registry.
111	Study Approval and Ethics statement
112	Informed consent from donor families was obtained prior to sample procurement.
113	Collection of QUOD samples and research ethics approval was provided by QUOD
114	(NW/18/0187).
115	Experimental Protocols and Statistical Analysis
116	See Supplementary Methods.
117	
118	RESULTS
119	Donor clinical and demographic variable relevance for eGFR at 12-month posttransplant
120	For exploratory analysis, we considered eGFR values in two ways. Firstly, to compare
121	clinical factors, we grouped 12 month posttransplant outcomes into tertiles; Suboptimal Outcome
122	(SO; eGFR≤39), Intermediate Outcome (IO; 40 <egfr≤59), (go;<="" and="" good="" outcome="" td=""></egfr≤59),>
123	eGFR $\geq$ 60), all units ml/min/1.73 m <sup>2</sup> (Figure 1). We refer to this henceforth as 'stratified eGFR'.
124	Secondly, all eGFR values (both recipient and donor) were rank-transformed so that we could
125	model against a continuum of outcomes while mitigating extreme values, or values recorded as 0
126	due to graft failure. We refer to 'ranked eGFR' henceforth to indicate ranked recipient eGFR at
127	12 months posttransplant.

128	Clinical metadata illustrated that stratified eGFR donor groups gave a balanced
129	representation of the UK donor population (Table 1), with no significant association between
130	donor type (DBD/DCD) and ranked eGFR (t-test; p=0.2028). We investigated associations
131	between clinical variables and stratified eGFR subgroups within each donor type, and between
132	donor types within stratified eGFR subgroups (Supplementary Table 1). There was a significant
133	difference in the current front-line selection score, the UK Kidney Donor Risk Index (UKKDRI) <sup>8</sup>
134	between outcome groups across donor types (ANOVA F-test; DBD: p=1.298e-6; DCD:
135	p=3.946e-7). In both donor types, the major component of UKKDRI, donor age, was
136	significantly different between outcome subgroups with donor age in SO being older (ANOVA
137	F-test; DBD: p=1.253e-9; DCD: p=1.196e-7). Histories of hypertension (also a component of
138	UKKDRI) were different between subgroups in DBD (ANOVA F-test; DBD: p=0.0020; DCD:
139	p=0.1069). Histories of diabetes (used in the US risk index, but not UKKDRI) were not
140	significantly different (ANOVA F-test; p=0.6188; DCD: p=0.2348). Terminal serum creatinine
141	levels were similar across outcome subgroups (ANOVA F-test; DBD: p=0.6972; DCD:
142	p=0.6448), although within the GO group it was higher in DBD than in DCD (t-test; p=0.0443).
143	After imputation of missing values, we examined associations between clinical variables
144	common to both DBD and DCD donors (Figure 2). The strongest associations with ranked eGFR
145	were donor age (Pearson's $r$ =-0.52), and recipient age ( $r$ =-0.28). Donor history of hypertension
146	and cardiological disease also clustered closely due to correlation with donor age ( $r=0.35$ and
147	r=0.33 respectively) but had a weaker direct correlation with outcome ( $r=0.30$ and $r=0.23$
148	respectively).

### 149 Unsupervised analysis of pretransplant kidney proteomes

Proteomic analysis quantified 2984 protein groups with 50% or less missing values (out of 7790 identified protein groups in total) over 185 samples and 20 interspersed sample pools (Supplementary Figure 1A). Analysis of sample pools showed minimal technical variance across sample acquisition (squared mean pairwise Z-corrected Pearson's r=0.94). Six samples were paired biopsies from the left and right kidneys of three donors. These samples showed high correlation of protein intensity values between donor pairs (Pearson's r=0.71, 0.92 and 0.91; Supplementary Figure 1B).

We explored the proteomic data using Principal Component Analysis (PCA) to find 157 underlying linear trends. Sample variance concentrated in the first two principal components 158 (PC1: 20.01%; PC2: 13.38%; Figure 3A). K-means clustering identified 4 distinct clusters 159 (Figure 3A) whose membership associated with donor type, with a preponderance of DBD 160 samples towards Cluster 2 and a preponderance of DCD samples towards Cluster 4 (Figure 3B, 161 162 upper left panel; p=0.0235). Clustering did not associate strongly with recipient ranked eGFR (p=0.4134), nor with donor ranked eGFR (p=0.1684), or donor age (p=0.7907) (Figure 3B, upper 163 middle, upper right and lower left panels). There was a weakly significant association between 164 cluster membership and donor BMI (p=0.0350) and with serum creatinine (p=0.0326) (Figure 165 3B, lower middle and lower right panels). 166

# Integration of kidney proteomes with clinical metadata enhances the resolution of donor kidney quality stratification

To identify possible clinical variable-protein interaction relationships with outcome, we used machine learning (Prediction Rule Ensembles<sup>22</sup>; PRE) to select features from the set of quantified proteins and all donor type-independent clinical variables.

We split our data into training and test sets, excluding the six paired kidneys, and sampling equally across stratified eGFR using a 2/3:1/3 train:test split. Test data was only used for validation (see below). The six paired kidneys were reserved as a second 'biological duplicates' test set.

A PRE model finds a minimal predictor set in the form of decision tree, linear regression 176 and multivariate adaptive regression spline<sup>24</sup> rules, but does not yield an exhaustive list of 177 predictors. We performed PRE iteratively, modelling against ranked eGFR; any proteins 178 identified in the final ensemble model of any iteration were excluded from the dataset in future 179 iterations, retaining only non-identified proteins plus all clinical variables. 2000 iterations of 180 181 PRE generated 3282 rules across all ensembles. The most common rules involved donor age, featuring as a term in 3154 (~96.1%) rules; in comparison, protein terms (collectively) featured 182 in 198 (~6.0%) rules, while the next largest non-protein term was donor group, featuring in 5 183 184 (~0.1%) rules (Figure 4A). Feature selection became progressively inefficient, in terms of candidate yield per iteration, however new candidates were still found up to termination at 185 iteration 2000. This process generated 195 candidate proteins; we supplemented this list with 186 proteins that had high correlation (Pearson's r > 0.65) with any of those candidates; bringing the 187 final list up to 255 candidates. 188

# 189 Regression spline modelling reveals protein associations with posttransplant outcome are 190 modulated by donor age

Next, we tested each protein candidate for individual association with outcome. Since
eGFR rank transformation is cohort specific, to generate results which generalized to other
settings we modelled against an outcome binary, calibrated against a population-level threshold.
Based on UK Renal Registry data, the donor type-weighted average median eGFR at 12 months

195	posttransplant since $2013^{25}$ was approximately ~50.25 ml/min/1.73 m <sup>2</sup> (±0.24 standard error; );
196	for simplicity we used a threshold of 50 ml/min/1.73 $m^2$ . We refer to 'sub-median outcome'
197	henceforth to refer to recipient eGFR at 12 months posttransplant less than 50 ml/min/1.73 $m^2$ .
198	Using multivariate adaptive regression spline modelling <sup>23</sup> to assess individual protein
199	relationships, we generated predictive models for sub-median outcome using each protein, donor
200	age, and age:protein interaction. This was performed in a regularized framework to retain only a
201	minimal set of predictors in each model. We discarded candidates whose model either did not
202	feature a protein or age:protein term, or gave a worse prediction error (Brier score <sup>26</sup> ) than donor
203	age alone.
204	After filtering we had identified 136 proteins which predicted sub-median outcome
205	(Supplementary Table 2). We performed a network analysis of shared Reactome pathways
206	(Figure 4). Walktrap clustering revealed 4 major clusters of shared-pathway proteins (Table 2);
207	Immune Regulation and Complement Activation, Protein Metabolism and Regulation,
208	Metabolism and Apoptosis.
209	For 124 proteins, the model included an age:protein interaction term where the predictive
210	effect of protein abundance was modulated by age, independent of the effect of age alone or
211	protein abundance alone (Figure 5, Supplementary Table 2). To visualize these effects, we used
212	each model to predict outcomes across increasing donor age for a high (90 <sup>th</sup> percentile), median
213	and low (10 <sup>th</sup> percentile) protein abundance (Figure 5A and Supplementary Figure 2). The
214	majority of proteins were positively associated with the chance of sub-median outcome
215	(simplistically, more protein = worse outcome), with the effect appearing to increase up to
216	around donor age 45-55, including representative proteins for all four major clusters including
217	known markers Cystatin-C (CST3; nephron function) and Vitronectin (VTN; fibrosis) as well as

a protein known for age-modulated disease associations, Apolipoprotein E (APOE). Several
proteins were negatively associated with the chance of sub-median outcome (simplistically more
protein = better outcome), with the largest effects shown by MAP2K1 and SLC27A2, the latter
in particular being modelled as having minimal effect in donors younger than 40. The selection
and filtering steps are summarized in Figure 5B.

### 223 Orthogonal validation confirms model performance, including age-modulated immuno-

### 224 metabolic impact on transplant outcomes

We adopted two orthogonal validation approaches. Firstly, we assessed the performance of each model on test data. Going from train to test data, the models showed a small increase in accuracy (Brier score; mean square error) and a small decrease in overall predictive performance as measured by the area under the curve (AUC) (Figure 6A), indicating that the models generalized well to unseen data, with most of the models (~110/136) showing almost no degradation in performance.

231 Secondly, we selected several cluster-representative proteins (VTN, APOE, CST3 and 232 Prolactin Regulatory Element Binding; PREB) that had robust available antibodies (Figure 6B). We investigated the predicted pattern of associations between protein abundance and outcome 233 (Figure 6C), by performing western blot validation of our results (Figure 6D). Selecting samples 234 235 with remaining material from our cohort from the Good and Suboptimal Outcome stratified eGFR tertiles of our sample set, we compared protein abundance between younger (oldest 236 sample 49) and older (youngest sample 58) donors. Our results were broadly consistent with the 237 238 associations anticipated by our modelling:

For VTN, our model suggests a strong association between protein abundance and
 outcome in younger donors that strengthens towards age 40-50 and then weakens. We observed a

significant difference in abundance by western blot between GO and SO outcome strata in
younger donors (t-test; p=2.107e-9) and a weaker but mildly significant difference in older
donors (t-test; p=0.0245).

For PREB, the model suggests that the age of maximum difference is shifted towards older donors compared to VTN; we did not observe any significant difference by western (t-test; p=0.4530) in young donors but did find such a difference in older donors (t-test, p=8.800e-5).

For APOE, the model suggests that the strongest association is over the middle of the age range, where outcome changes rapidly with donor age, followed by a weaker but consistent association from donor age 49-50 onwards. We observed no difference among younger donors, although examination of the sampled age ranges indicate the area of starkest difference was under-sampled (Figure 5C; t-test, p=0.3719). In older donors, we saw a mildly significant difference in APOE abundance between outcomes (t-test, p=0.0323).

For CST3, the model again predicted a strong association in young donors which then weakens (and even reverses, such that GO samples would tend to have higher CST3 than SO samples); in younger donor western blots we observed a significant difference (t-test, p=0.0084) between GO and SO, while in older donors we saw a nonsignificant difference, but (in contrast to the prediction) still with a positive median protein abundance difference from GO to SO.

Finally, we compared the predicted outcome for each of the six paired kidneys from the second 'biological duplicates' test set against their actual recipient eGFR at 12 months posttransplant (Figure 6E). All three kidney pairs in this dataset had consistent outcomes across pairs; two pairs with sub-median outcome (15 and 36 ml/min/1.73 m<sup>2</sup>; 23 and 27 ml/min/1.73 m<sup>2</sup>) and one pair with above-median outcome (72 and 81 ml/min/1.73 m<sup>2</sup>); all four protein models assigned the four kidneys from the two sub-median outcome donors a probability of sub-

median outcome greater than 0.6 (except in one case for PREB, where it was 0.48), and assigned
both kidneys from the above-median outcome donor a probability of sub-median outcome less
that 0.3.

### 267 **DISCUSSION**

Increasingly, shortages of optimal organs require utilization of kidneys from older deceased donors with increased risks of graft failure or functional decline. Here, we show that age-modulated kidney proteomic profiles improve risk stratification of donor kidney quality, revealing clinically relevant age-protein interaction effects.

Donor age remains a key contributor in these clinical decisions and is rightfully one of 272 the most strongly weighted terms in extant scoring systems to determine kidney allocation<sup>8,27</sup>. In 273 274 our analysis, we found no obvious difference according to age when comparing donor kidney proteomes by unbiased PCA. However, looking specifically at outcomes, it was the single most 275 important factor. PCA considers only a linear combination of variables and is ill-suited to 276 277 exploring nonlinear effects or interaction between variables. When we explored our data with our 278 iterative PRE feature selection approach, a substantial number of proteins were revealed to be relevant. 279

The effect of donor age is not a novel finding, but integration of the age and proteomic information resulted in enhanced prediction of 12 month sub-median function without reference to other currently considered clinical factors. In particular, a factor often described as relevant to transplant outcome is donor type<sup>28</sup>. This is true at a clinical level in terms of donor management, and donation after circulatory death is considered an adverse factor for transplant outcome in the  $US^7$  (although not in the  $UK^{8,29}$ ). Our initial PCA analysis found that non-supervised clustering of the sample proteomes did partially separate samples by type but did not extend to association

with outcome. Weaker association may be obscured by factors associated with the overwhelming effect of donor age, but (without disputing donor type-specific mechanisms of kidney injury<sup>30</sup>), our data are consistent with the idea that extent of injury (rather than the cause) is the primary contributor towards recovery potential<sup>31</sup>.

Within our final list of 136 proteins associated with outcome there is a common theme of 291 implication in immune response to kidney injury (including both chronic injury, and acute 292 injury) particularly as a result of ischemic metabolic disruption. Our analysis of proteins 293 associated with outcome also revealed that most (124/136) proteins showed age-moderated 294 differences in their effect; for most proteins manifesting as a stronger negative association 295 296 between abundance and outcome starting around donor age 40-50. This second-order age interaction effect, where weightings of other factors are themselves age dependent, has not (to 297 our knowledge) been explored in transplantation, and may be key to fully understanding the 298 299 effects of molecular predictors.

A prominent age-modulated example of a chronic injury associated marker in our 300 candidate list is VTN, a primary component of the extracellular matrix involved in in cell 301 adhesion, enhancing the activity of plasminogen activator inhibitor-1 and inhibition of the 302 terminal complement pathway<sup>32</sup>. Vitronectin has been suggested as a biomarker of kidney 303 fibrosis, although the mode of its multifaced action needs further investigation<sup>33</sup>. Further acute 304 305 injury associated markers include components of the membrane attack complex, C5 (in the form 306 of C5b cleavage product) and C8A, which has been associated with tissue injury resulting from ischemia/reperfusion<sup>34,35</sup>, Complement Component 1r (C1R), part of the activation complex for 307 the classical complement pathway<sup>36</sup>, and Complement Factor B (CFB), a component of the 308 309 alternative pathway. Another candidate associated with immune regulation is Maltase

Glucoamylase (MGAM), characterized as an intestinal enterocyte but with expression in several
 tissues including kidney, and whose presence in urinary exosomes been cited as a marker of AKI
 in cirrhosis patients<sup>37</sup>.

Mitogen-activated protein kinase 1 (MAP2K1, aka MEK1), a key component of the MAP kinase signal transduction pathway and closely involved in both cellular control and immune regulation (as part of TNF<sup>2</sup> signaling response<sup>38</sup>), is notable as one of the few proteins for which higher abundance was associated with a reduced probability of sub-median outcome, indicating resilience to injury. Increased TNF<sup>2</sup> is more usually associated with renal injury<sup>39</sup>, so this result is counterintuitive. The MAPK/ERK cascade impacts many regulatory pathways so it is reasonable to assume such intuition may oversimplify the effect of increased MEK1 abundance.

320 Several age-moderated proteins we report are characterized as markers of protein regulation and proteasomal activity, suggesting alterations within the proteostasis network that 321 increase susceptibility of donor grafts to subsequent injury and reduce capacity for recovery. 322 CST3 is particularly noteworthy as, measured in serum, it is a known and effective general 323 biomarker for kidney function and has previously been reported as having predictive power for 324 outcomes in transplant recipients<sup>40-42</sup>. Our evidence indicates a further association between 325 CST3 levels in the donor kidney tissue and outcome; moreover, that this effect is age dependent, 326 starting around age 40. Interestingly, while serum CST3 is relatively independent of age in 327 children and young adults<sup>43</sup>, there is some evidence for an increase in later years<sup>44</sup>. 328

We found the age-modulated candidate PREB (Prolactin Regulatory Element Binding protein) biologically interesting for three reasons. Firstly, there is a well characterized relationships between kidney dysfunction (in the form of CKD), cardiovascular disease and prolactinemia<sup>45</sup>, with CKD patients being associated with elevated prolactinemia. Secondly, it is

a regulator of glucose homeostasis in the liver and therefore a plausible key node for metabolic regulation in kidneys as well<sup>46</sup>, acknowledging the large emphasis in our pathway analysis on metabolic functions. Thirdly, it has a predicted<sup>47</sup> role in exit from the endoplasmic reticulum and the unfolded protein response, which has an association with CKD via NF $\kappa$ B -mediated inflammation<sup>48</sup>.

Another age-moderated protein, APOE, stands out as having previously reported genetic 338 allele age-related associations with disease and organ dysfunction including risk of Alzheimer's 339 Disease  $(AD)^{57}$  (with the strongest effect manifesting around age  $65^{58}$ ), macular dysfunction, 340 atherosclerosis and pulmonary scarring<sup>59,60</sup>, and evidence for shared allele risk across diseases<sup>61</sup>. 341 In kidneys, APOE plays an important role in lipid metabolism to regulate the growth and 342 survival of mesangial cells and preserve organ function<sup>49</sup>; it is a marker for outcome in transplant 343 recipients 50-52, and there is already evidence for APOE genetic allele association with kidney 344 dysfunction risk<sup>53–55</sup>, possibly manifested by lipidomic differences between allelic profiles<sup>56</sup>. We 345 have previously observed small (not statistically significant) increases in APOE due to ischemic 346 reperfusion injuries<sup>62</sup> possibly explained by a recent description of the role of APOE in 347 mediating senescence<sup>63</sup>. Such evidence supports further in-depth investigation of the APOE 348 genotype in outcomes across donor kidney age. There is existing evidence for similar allele 349 dependent transplant outcome effects in another apolipoprotein (APOL1)<sup>64</sup>, suggesting that the 350 broader apolipoprotein allelic profile may play an important role in outcome. 351

Our list of outcome-associated candidates, controlling for the effect of donor age, including those for which we report a further age-moderated effect, cannot be exhaustive. Practicalities of sample acquisition limited sampling of a wide range of outcomes outside the 30-60 donor age range, especially limited good outcome events at high donor age. Organ allocation

algorithms impose a close link between donor and recipient age in the sample cohort, so while
we interpret these age-moderated effects in terms of organ resilience in older donors, it could
also represent a greater ability to repair a given level of damage in younger recipients. Further,
we consider only chronological donor age, rather than a more nuanced representation of the
epigenomic biological clock <sup>65</sup>, which may to account for some variation observed with respect
to both donors and recipients.

In the vast majority of proteins, the modelling suggests a plateauing effect at high donor 362 age where the differences in outcome due to both protein and age are smaller. This effect may be 363 an artifact of the distribution of sub-median outcomes in our UK population-representative data 364 365 (>95% sub-median outcome above age 60 in our training set). The protein abundance differences between GO and SO outcomes in our western blot validation were broadly consistent with our 366 differences expected given our prediction models. There were some differences; firstly, the 367 differences in both VTN and PREB in older donors were larger than might be expected by 368 examination of the prediction curves (Figure 6B, upper panel); secondly, the prediction for CST3 369 of a small reversal of the effect is both unexpected and biologically counterintuitive. Both 370 examples are most readily explained as model artifacts due to lack of outcome diversity at high 371 372 age ranges.

It is immediately clear from our results that the strength of the donor age factor is enormous relative to any other protein or clinical effect; this age effect is liable to dominate any prediction weighting and reduce the accuracy of estimated protein contribution. A much larger cohort could mitigate this issue. Advances in high-throughput proteomics techniques continue to increase feasible cohort sizes<sup>66</sup> but fundamental limitations on organ acquisition remain. Archiving at scale of clinical samples in bioresources such as the QUOD biobank to parallel

advancements in big data analysis and interpretation platforms is therefore necessary for future
 development of granular evidence-based decision making.

In this work, we profiled the proteome of pre-implantation biopsies selected from donor 381 kidneys on the basis of paired 12-month graft function. Using machine learning and regression 382 models, we identified 136 proteins associated with sub-median outcomes, suggesting molecular 383 signatures which may refine models of graft dysfunction based on clinical and demographic 384 factors alone. We also found that most of these proteins furthermore show donor-age modulated 385 association. The biological themes of the identified proteins reinforce known immuno-metabolic 386 mechanisms of kidney injury but raise interesting possibilities for further work, especially with 387 388 regard to donor genetic background, and also suggest that the possibility of donor age-moderated weighting should be considered as a matter of course in future work. 389

390

#### 391 SUPPLEMENTARY MATERIALS

392 Supplementary Methods

393 Supplementary Table 1: Clinical variable p-values for association with donor type and outcome

394 Supplementary Table 2: Summary of results for all candidate proteins

395 Supplementary Figure 1: Protein quantification quality

A: Missingness comparison: Proteins are shown ranked by the number of missing values

- 397 across all samples and the twenty standard pools, excluding one run which was removed
- due to low signal. 2984 proteins had missing values in 50% or less runs.
- B: Paired Kidney Comparison: Protein abundance values from paired kidneys (left/right)
- 400 from 3 individual donors were compared, as these are effectively biological replicates. x
- 401 axes: value in left kidney. y axes: value in right kidney. Inset: R-squared value

402	Supplementary Figure 2: Prediction of sub-median outcome differences between high and low
403	protein across donor age, for all shortlisted proteins with a predicted age modulation effect
404	Black traces: prediction at median protein abundance. Purple trace: prediction at 90th
405	percentile of protein abundance. Orange traces: prediction at 10th percentile of protein
406	abundance. The corresponding point on the main figure thus indicates the age at which
407	the difference between orange and purple lines is greatest.
408	
409	DATA AND MATERIALS AVAILABILITY
410	The mass spectrometry proteomics data have been deposited to the ProteomeXchange
411	Consortium via the PRIDE <sup>67</sup> partner repository with the dataset identifier PXD033428.
412	
413	DISCLOSURE AND FUNDING

- 414 This study was supported by NHS Blood and Transplant funding awarded to MK & RJP. SF
- 415 was supported by Kidney Research UK, grant reference KS\_RP\_002\_20210111 awarded to MK.
- 416 PDC was supported by a Chinese Academy of Medical Sciences 2018-I2M-2-002 awarded to
- 417 BMK. Authors declare that they have no competing interests.

### 418 **Author contributions:**

- 419 Conceptualization: MK
- 420 Methodology: PDC, SF, RV, SD, RF, BMK, AS, ES, RJP, MK
- 421 Investigation: PDC, SF, RV, PJ, SD, IV, KT, AS
- 422 Visualization: PDC
- 423 Funding acquisition: BMK, RJP, MK

424	Project administration: MK
-----	----------------------------

- 425 Supervision: RF, AS, MK
- 426 Writing original draft: PDC, ES, MK
- 427 Writing review & editing: All authors
- 428

### 429 **REFERENCES**

- Callaghan CJ, Mumford L, Pankhurst L, Baker RJ, Bradley JA, Watson CJE. Early
   Outcomes of the New UK Deceased Donor Kidney Fast-Track Offering Scheme.
   *Transplantation*. 2017;101(12):2888-2897. doi:10.1097/TP.00000000001860
- Summers DM, Johnson RJ, Hudson AJ, et al. Standardized deceased donor kidney donation rates in the UK reveal marked regional variation and highlight the potential for increasing kidney donation: a prospective cohort study<sup>†</sup>. *Br J Anaesth*. 2014;113(1):83-90. doi:10.1093/bja/aet473
- 437 3. Denic A, Glassock RJ, Rule AD. The Kidney in Normal Aging: A Comparison with Chronic
  438 Kidney Disease. *Clin J Am Soc Nephrol*. 2022;17(1):137-139. doi:10.2215/CJN.10580821
- 4. O'Hare AM, Choi AI, Bertenthal D, et al. Age affects outcomes in chronic kidney disease. J
   440 Am Soc Nephrol. 2007;18(10):2758-2765. doi:10.1681/ASN.2007040422
- Ishani A, Xue JL, Himmelfarb J, et al. Acute Kidney Injury Increases Risk of ESRD among
  Elderly. *J Am Soc Nephrol.* 2009;20(1):223-228. doi:10.1681/ASN.2007080837
- 6. Summers DM, Johnson RJ, Hudson A, Collett D, Watson CJ, Bradley JA. Effect of donor
  age and cold storage time on outcome in recipients of kidneys donated after circulatory death
  in the UK: a cohort study. *Lancet*. 2013;381(9868):727-734. doi:10.1016/S01406736(12)61685-7
- Rao PS, Schaubel DE, Guidinger MK, et al. A comprehensive risk quantification score for
  deceased donor kidneys: the kidney donor risk index. *Transplantation*. 2009;88(2):231-236.
  doi:10.1097/TP.0b013e3181ac620b
- Watson CJE, Johnson RJ, Birch R, Collett D, Bradley JA. A Simplified Donor Risk Index
   for Predicting Outcome After Deceased Donor Kidney Transplantation. *Transplantation*.
   2012;93(3):314-318. doi:10.1097/TP.0b013e31823f14d4
- 453 9. Neuberger J, Callaghan C. Organ utilization the next hurdle in transplantation? *Transpl Int.*454 2020;33(12):1597-1609. doi:10.1111/tri.13744

10. Clayton PA, Dansie K, Sypek MP, et al. External validation of the US and UK kidney donor
 risk indices for deceased donor kidney transplant survival in the Australian and New Zealand
 population. *Nephrol Dial Transplant*. 2019;34(12):2127-2131. doi:10.1093/NDT/GFZ090

11. Remuzzi G, Cravedi P, Perna A, et al. Long-Term Outcome of Renal Transplantation from 458 Older Donors. N Engl J Med. 2006;354(4):343-352. doi:10.1056/NEJMoa052891 459 12. Husain SA, Chiles MC, Lee S, et al. Characteristics and Performance of Unilateral Kidney 460 Transplants from Deceased Donors. Clin J Am Soc Nephrol. 2018;13(1):118-127. 461 doi:10.2215/CJN.06550617 462 13. Liu C, Hall IE, Mansour S, Thiessen Philbrook HR, Jia Y, Parikh CR. Association of 463 Deceased Donor Acute Kidney Injury With Recipient Graft Survival. JAMA Network Open. 464 2020;3(1):e1918634. doi:10.1001/jamanetworkopen.2019.18634 465 14. Yu K, Husain SA, King K, Stevens JS, Parikh CR, Mohan S. Kidney nonprocurement in 466 deceased donors with acute kidney injury. Clin Transplant. Published online August 4, 467 2022:e14788. doi:10.1111/ctr.14788 468 15. Hall IE, Akalin E, Bromberg JS, et al. Deceased-donor acute kidney injury is not associated 469 with kidney allograft failure. Kidney Int. 2019;95(1):199-209. 470 doi:10.1016/j.kint.2018.08.047 471 472 16. Mansour SG, Khoury N, Kodali R, et al. Clinically adjudicated deceased donor acute kidney injury and graft outcomes. PLoS One. 2022;17(3):e0264329. 473 doi:10.1371/journal.pone.0264329 474 17. von Moos S, Akalin E, Mas V, Mueller TF. Assessment of Organ Quality in Kidney 475 Transplantation by Molecular Analysis and Why It May Not Have Been Achieved, Yet. 476 477 Front Immunol. 2020;11:833. doi:10.3389/fimmu.2020.00833 18. Gillet LC, Navarro P, Tate S, et al. Targeted data extraction of the MS/MS spectra generated 478 479 by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol Cell Proteomics. 2012;11(6):O111.016717. doi:10.1074/mcp.O111.016717 480 19. Geyer PE, Holdt LM, Teupser D, Mann M. Revisiting biomarker discovery by plasma 481 proteomics. Mol Syst Biol. 2017;13(9):942. doi:10.15252/msb.20156297 482 20. Connor KL, O'Sullivan ED, Marson LP, Wigmore SJ, Harrison EM. The Future Role of 483 Machine Learning in Clinical Transplantation. Transplantation. 2021;105(4):723-735. 484 doi:10.1097/TP.00000000003424 485 21. Raynaud M, Aubert O, Divard G, et al. Dynamic prediction of renal survival among deeply 486 phenotyped kidney transplant recipients using artificial intelligence: an observational, 487 international, multicohort study. The Lancet Digital Health. 2021;3(12):e795-e805. 488 doi:10.1016/S2589-7500(21)00209-0 489 22. Fokkema M. Fitting prediction rule ensembles with R package pre. J Stat Softw. 490 2020;92(1):1-30. doi:10.18637/jss.v092.i12 491 23. Friedman JH. Multivariate Adaptive Regression Splines. aos. 1991;19(1):1-67. 492 doi:10.1214/aos/1176347963 493

- 494 24. Milborrow. Derived from mda:mars by T. Hastie and R. Tibshirani. S. *Earth: Multivariate* 495 *Adaptive Regression Splines.*; 2011. http://CRAN.R-project.org/package=earth
- 496 25. UK Renal Registry. UK Renal Registry 24th Annual Report Data to 31/12/2020.; 2022.
   497 https://renal.org/audit-research/annual-report
- 498 26. Brier GW. Verification Of Forecasts Expressed In Terms Of Probability. *Mon Weather Rev.*499 1950;78(1):1-3. doi:10.1175/1520-0493(1950)078<0001:VOFEIT>2.0.CO;2
- Li B, Cairns JA, Robb ML, et al. Predicting patient survival after deceased donor kidney
   transplantation using flexible parametric modelling. *BMC Nephrol*. 2016;17(1):51.
   doi:10.1186/s12882-016-0264-0
- Single States 28. Gill J, Rose C, Lesage J, Joffres Y, Gill J, O'Connor K. Use and Outcomes of Kidneys from
  Donation after Circulatory Death Donors in the United States. *J Am Soc Nephrol.*2017;28(12):3647-3657. doi:10.1681/asn.2017030238
- 29. Robinson C. *NHSBT Policy POL186/10. Kidney Transplantation: Deceased Donor Allocation.*; 2019. https://nhsbtdbe.blob.core.windows.net/umbraco-assets corp/16915/kidney-allocation-policy-pol186.pdf
- 30. Vaughan RH, Kresse JC, Farmer LK, et al. Cytoskeletal protein degradation in brain death
   donor kidneys associates with adverse post-transplant outcomes. *Am J Transplant*. Published
   online December 8, 2021. doi:10.1111/ajt.16912
- 512 31. Kosmoliaptsis V, Salji M, Bardsley V, et al. Baseline donor chronic renal injury confers the
   513 same transplant survival disadvantage for DCD and DBD kidneys. *Am J Transplant*.
   514 2015;15(3):754-763. doi:10.1111/ajt.13009
- 515 32. De Lorenzi V, Sarra Ferraris GM, Madsen JB, Lupia M, Andreasen PA, Sidenius N.
  516 Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in 517 vitronectin. *EMBO Rep.* 2016;17(7):982-998. doi:10.15252/embr.201541681
- 33. Carreras-Planella L, Cucchiari D, Cañas L, et al. Urinary vitronectin identifies patients with
  high levels of fibrosis in kidney grafts. *J Nephrol*. 2021;34(3):861-874. doi:10.1007/s40620020-00886-y
- 521 34. Diepenhorst GMP, van Gulik TM, Hack CE. Complement-mediated ischemia-reperfusion
   522 injury: lessons learned from animal and clinical studies. *Ann Surg.* 2009;249(6):889-899.
   523 doi:10.1097/SLA.0b013e3181a38f45
- Arias-Cabrales CE, Riera M, Pérez-Sáez MJ, et al. Activation of final complement
   components after kidney transplantation as a marker of delayed graft function severity. *Clin Kidney J.* 2021;14(4):1190-1196. doi:10.1093/ckj/sfaa147
- 36. Almitairi JOM, Venkatraman Girija U, Furze CM, et al. Structure of the C1r-C1s interaction
  of the C1 complex of complement activation. *Proc Natl Acad Sci U S A*. 2018;115(4):768773. doi:10.1073/pnas.1718709115

- 37. Awdishu L, Tsunoda S, Pearlman M, et al. Identification of Maltase Glucoamylase as a
  Biomarker of Acute Kidney Injury in Patients with Cirrhosis. *Crit Care Res Pract*.
  2019;2019:5912804. doi:10.1155/2019/5912804
- 38. Sabio G, Davis RJ. TNF and MAP kinase signalling pathways. *Semin Immunol*.
  2014;26(3):237-245. doi:10.1016/j.smim.2014.02.009
- 39. Ernandez T, Mayadas TN. Immunoregulatory role of TNFalpha in inflammatory kidney
   diseases. *Kidney Int*. 2009;76(3):262-276. doi:10.1038/ki.2009.142
- 40. Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive
  estimation of glomerular filtration rate and as a marker for early renal impairment. *Am J Kidney Dis.* 2000;36(1):29-34. doi:10.1053/ajkd.2000.8237
- 41. Christensson A, Ekberg J, Grubb A, Ekberg H, Lindström V, Lilja H. Serum cystatin C is a
  more sensitive and more accurate marker of glomerular filtration rate than enzymatic
  measurements of creatinine in renal transplantation. *Nephron Physiol.* 2003;94(2):19-27.
  doi:10.1159/000071287
- 42. Rodrigo E, Ruiz JC, Fernández-Fresnedo G, et al. Cystatin C and albuminuria as predictors
  of long-term allograft outcomes in kidney transplant recipients. *Clin Transplant*.
  2013;27(2):E177-83. doi:10.1111/ctr.12082
- 43. Bökenkamp A, Domanetzki M, Zinck R, Schumann G, Byrd D, Brodehl J. Cystatin C--a
  new marker of glomerular filtration rate in children independent of age and height. *Pediatrics*. 1998;101(5):875-881. doi:10.1542/peds.101.5.875
- 44. Edinga-Melenge BE, Yakam AT, Nansseu JR, et al. Reference intervals for serum cystatin C
  and serum creatinine in an adult sub-Saharan African population. *BMC Clin Pathol*.
  2019;19:4. doi:10.1186/s12907-019-0086-7
- 45. Dourado M, Cavalcanti F, Vilar L, Cantilino A. Relationship between Prolactin, Chronic
  Kidney Disease, and Cardiovascular Risk. *Int J Endocrinol*. 2020;2020:9524839.
  doi:10.1155/2020/9524839
- 46. Park JM, Kim MY, Kim TH, Min DK, Yang GE, Ahn YH. Prolactin regulatory elementbinding (PREB) protein regulates hepatic glucose homeostasis. *Biochim Biophys Acta Mol Basis Dis.* 2018;1864(6 Pt A):2097-2107. doi:10.1016/j.bbadis.2018.03.024
- 47. Gaudet P, Livstone MS, Lewis SE, Thomas PD. Phylogenetic-based propagation of
  functional annotations within the Gene Ontology consortium. *Brief Bioinform*.
  2011;12(5):449-462. doi:10.1093/bib/bbr042
- 48. Mohammed-Ali Z, Cruz GL, Dickhout JG. Crosstalk between the unfolded protein response
   and NF-κB-mediated inflammation in the progression of chronic kidney disease. *J Immunol Res.* 2015;2015:428508. doi:10.1155/2015/428508
- 49. Chen G, Paka L, Kako Y, Singhal P, Duan W, Pillarisetti S. A Protective Role for Kidney
   Apolipoprotein E: REGULATION OF MESANGIAL CELL PROLIFERATION AND

- 567 MATRIX EXPANSION. J Biol Chem. 2001;276(52):49142-49147.
   568 doi:10.1074/JBC.M104879200
- 50. Kahraman S, Kiykim AA, Altun B, et al. Apolipoprotein E gene polymorphism in renal
   transplant recipients: effects on lipid metabolism, atherosclerosis and allograft function. *Clin Transplant*. 2004;18(3):288-294. doi:10.1111/j.1399-0012.2004.00162.x
- 572 51. Hernández D, Salido E, Linares J, et al. Role of apolipoprotein E epsilon 4 allele on chronic
  573 allograft nephropathy after renal transplantation. *Transplant Proc.* 2004;36(10):2982-2984.
  574 doi:10.1016/j.transproceed.2004.10.038
- 575 52. Cofán F, Cofan M, Rosich E, et al. Effect of apolipoprotein E polymorphism on renal transplantation. *Transplant Proc.* 2007;39(7):2217-2218.
  577 doi:10.1016/j.transproceed.2007.06.011
- 578 53. Czaplińska M, Ćwiklińska A, Sakowicz-Burkiewicz M, et al. Apolipoprotein e gene
  579 polymorphism and renal function are associated with apolipoprotein e concentration in
  580 patients with chronic kidney disease. *Lipids Health Dis.* 2019;18(1):1-9.
  581 doi:10.1186/s12944-019-1003-x
- 582 54. Hsu CC, Kao WHL, Coresh J, et al. Apolipoprotein E and progression of chronic kidney
   583 disease. *J Am Med Assoc*. 2005;293(23):2892-2899. doi:10.1001/jama.293.23.2892
- 584 55. Saito T, Ishigaki Y, Oikawa S, Yamamoto TT. Etiological significance of apolipoprotein E
  mutations in lipoprotein glomerulopathy. *Trends Cardiovasc Med*. 2002;12(2):67-70.
  doi:10.1016/S1050-1738(01)00148-7
- 587 56. Sienski G, Narayan P, Bonner JM, et al. APOE4 disrupts intracellular lipid homeostasis in
  588 human iPSC-derived glia. *Sci Transl Med.* 2021;13(583):eaaz4564.
  589 doi:10.1126/scitranslmed.aaz4564
- 590 57. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk,
  591 mechanisms, and therapy. *Nat Rev Neurol*. 2013;9(2):106-118.
  592 doi:10.1038/nrneurol.2012.263
- 58. Saddiki H, Fayosse A, Cognat E, et al. Age and the association between apolipoprotein E
   genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study.
   *PLoS Med.* 2020;17(8):e1003289. doi:10.1371/journal.pmed.1003289
- 596 59. Mahley RW, Rall SC. Apolipoprotein E: far more than a lipid transport protein. *Annu Rev* 597 *Genomics Hum Genet*. 2000;1:507-537. doi:10.1146/annurev.genom.1.1.507
- 598 60. Yao X, Gordon EM, Figueroa DM, Barochia AV, Levine SJ. Emerging Roles of
  599 Apolipoprotein E and Apolipoprotein A-I in the Pathogenesis and Treatment of Lung
  600 Disease. *Am J Respir Cell Mol Biol*. 2016;55(2):159-169. doi:10.1165/rcmb.2016-0060TR
- 61. Miwa K, Tanaka M, Okazaki S, et al. Chronic kidney disease is associated with dementia
  independent of cerebral small-vessel disease. *Neurology*. 2014;82(12):1051-1057.
  doi:10.1212/WNL.0000000000251

- 604 62. Huang H, van Dullemen LFA, Akhtar MZ, et al. Proteo-metabolomics reveals compensation
  605 between ischemic and non-injured contralateral kidneys after reperfusion. *Sci Rep.*606 2018;8(1):8539. doi:10.1038/s41598-018-26804-8
- 607 63. Zhao H, Ji Q, Wu Z, et al. Destabilizing heterochromatin by APOE mediates senescence.
   608 *Nature Aging*. 2022;2(4):303-316. doi:10.1038/s43587-022-00186-z
- 609 64. Julian BA, Gaston RS, Brown WM, et al. Effect of Replacing Race with Apolipoprotein L1
  610 Genotype in Calculation of Kidney Donor Risk Index. *Am J Transplant*. 2017;17(6):1540.
  611 doi:10.1111/AJT.14113
- 612 65. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of 613 ageing. *Nat Rev Genet*. 2018;19(6):371-384. doi:10.1038/s41576-018-0004-3
- 66. Meier F, Brunner AD, Frank M, et al. diaPASEF: parallel accumulation–serial fragmentation
  combined with data-independent acquisition. *Nat Methods*. 2020;17(12):1229-1236.
  doi:10.1038/s41592-020-00998-0
- 67. Perez-Riverol Y, Csordas A, Bai J, et al. The PRIDE database and related tools and
   resources in 2019: improving support for quantification data. *Nucleic Acids Res*.
   2019;47(D1):D442-D450. doi:10.1093/nar/gky1106
- 620

### 621 ACKNOWLEDGMENTS

- We thank the UK QUOD Consortium and NHS Blood and Transplant UK Registry for providing
- the samples and the associated clinical and demographic metadata. ; in particular we thank Sheba
- 24 Ziyenge, Lewis Simmonds and Dr Sarah Cross, Dr Sergei Maslau and Mr Tomas Surik for their
- support on the QUOD sample selection.
- 626 We thank members of the Discovery Proteomics Facility within the TDI Mass Spectrometry
- Laboratory for expert help with mass spectrometry analysis, and members of the Lindgren group
- at the BDI for informative discussions regarding statistical modelling.

### 629 FIGURES AND TABLES



### 630 Figure 1: Experimental design to discover donor kidney proteome associations with transplant outcome

631 One kidney from each donor pair was biopsied at the back table. Donor kidney samples were selected randomly

from pairs where both recipients had similar outcomes. The biopsy samples were subjected to proteomic analysis to

yield a snapshot of the organ proteome before transplantation. We analyzed donor characteristics and clinical
 variables, recipient characteristics and protein abundances in a combined model against outcome. eGFR units for

635 stratification given in ml/min/1.73 m<sup>2</sup>.

Donor Type		DBD			DCD	
Outcome	1 <sup>st</sup> •	$2^{\mathrm{nd}}$ .	3 <sup>rd:</sup>	1 <sup>st</sup> ·	$2^{\mathrm{nd}}$ .	3 <sup>rd:</sup>
Tertile	Subontimal	ے ۔ Intermediate	Good	Suboptimal	∠ . Intermediate	Good
(eGFR in	$(eGFR \leq 39)$	$(40 \le eGFR \le 59)$	(eGFR≥60)	$(eGFR \leq 39)$	$(40 \le eGFR \le 59)$	( <i>eGFR</i> ≥60)
$\frac{ml/min/1.73 m^2}{p}$	31	21	38	21	28	26
11	51	51 22	20.05	51	20	20
Donor Age, y	56.84 + 12.29	51.32 + 12.24	39.05 + 14.12	55.48 + 9.34	53.57 +9.75	38.31 + 12.28
Donor Sex				- /		
Mala	15	16	19	22	16	16
Iviale	(48.4%)	(51.6%)	(50.0%)	(71.0%)	(57.1%)	(61.5%)
Female	16	15	19	9	12	10
-	(51.6%)	(48.4%)	(50.0%)	(29.0%)	(42.9%)	(38.5%)
Donor						
Ethnicity	• •	•			• •	
White	30	30	36	30	28	25
	(96.8%)	(96.8%)	(94.7%)	(96.8%)	(100.0%)	(96.2%)
Other	1 (2.2%)	1 (2.2%)	(5.2%)	1	(0.0%)	1
Donor	(3.2%)	(3.2%)	01 20	(3.2%)	(0.0%)	(3.8%)
Weight kg	62.35 + 18.20	70.01 + 18.07	01.30 + 17.72	00.30 + 14.95	02.43 + 17.20	/ 0.0 / + 13.96
Donor	1.0.42	1.0.52	174.92	1(0.07	171 64	174.65
Dolloi Hoight om	108.42	169.52	1/4.82	169.97	1/1.04	1/4.65
Deper S Cr	± 9.37	± 7.07	± 11.10	± 7.90	± 9.73	± 0.90
Donor S-Cr	86.54	82.57	90.19	73.37	70.31	59.60
terminal,	$\pm 40.81$	$\pm 49.65$	$\pm 67.36$	± 19.03	$\pm 39.02$	$\pm 22.39$
μποι/τ	15.00	14.20	12.40	12.65	11.70	12.00
Donor CIT, h	15.80	14.20	13.42	15.05	11.72	12.80
Donor COD	1 3.88	± 4.00	± 4.07	± 5.20	± 5.55	± 4.49
Dollor COD	1	2	2	4	2	4
Trauma	(2, 20%)	<b>3</b> (0.7%)	<b>3</b> (7.0%)	(12.0%)	3 (10.7%)	4
	30	(9.7%)	35	(12.9%)	25	(13.4%)
Other	(96.8%)	(90.3%)	(92.1%)	(87.1%)	(89.3%)	(84.6%)
Donor	1.41	1.10	0.85	1.31	1.21	0.73
UKKDRI	± 0.52	± 0.36	± 0.36	± 0.37	$\pm 0.40$	± 0.35
Recipient	53.03	52.10	39 71	51.90	50.93	44 92
Age, v	± 12.21	± 14.61	$\pm 16.03$	± 9.85	± 11.04	± 12.87
Recipient Sex						
Recipient bex	15	8	12	11	0	5
Female	(48.4%)	(25.8%)	(31.6%)	(35.5%)	(32.1%)	(19.2%)
M. 1.	16	23	26	20	19	21
Iviale	(51.6%)	(74.2%)	(68.4%)	(64.5%)	(67.9%)	(80.8%)
Recipient Ethnicity						
White	24	21	29	22	23	20
w mite	(77.4%)	(67.7%)	(76.3%)	(71.0%)	(82.1%)	(76.9%)
Other	7	10	9	9	5	6
	(22.6%)	(32.3%)	(23.7%)	(29.0%)	(17.9%)	(23.1%)
Recipient Posttransplant Kidney Function (mean eGFR, ml/min/1.73 m <sup>2</sup> )						
3 months	29.71	50.32	78.54	31.72	46.50	77.88
5 months	± 12.06	± 17.28	± 25.97	± 12.24	± 10.34	± 18.57
12 months	26.58	49.58	85.58	25.10	48.24	80.26
	± 11.98	± 6.10	$\pm 35.84$	± 12.01	± 6.29	$\pm 15.91$

636 Table 1: Donor and recipient clinical and demographic variables

637 Donor kidney associated metadata. Samples are subdivided by donor type and by final assigned outcome tertile.

638 Numerical variables are given  $\pm$  standard deviation. Categorial variables are given alongside percentage of total 639 cohort





641 Single-linkage hierarchical clustering of curated, imputed clinical variables by relative association strength (taking

distance as 1-association). The outcome variable (ranked recipient eGFR at 12 months post-transplantation) is
 highlighted in red.



644 Figure 3: Unbiased analysis of pretransplant kidney proteomes and cluster associations

A: Unbiased analysis of proteomic data by k-means clustering. Sample separation by Principal Component Analysis.
 Top Left: Samples were assigned to four clusters by k-means. Bottom & Right: There was a difference in the
 distribution of DBD and DCD donors across clusters, with the DBD donors being more heavily concentrated in

Cluster 2 ('+' symbol; orange shading), and DCD in Cluster 4 ('x' symbol; pink shading)

B: There were no associations between proteome clusters and most donor and recipient factors, except for mildly

- significant differences in donor BMI and creatinine (selected comparisons shown; left-right, top-bottom: donor type,
   recipient 12-month posttransplant eGFR (outcome), donor eGFR, donor age, donor BMI, donor creatinine at
- 652 retrieval).



### Figure 4: Age and combined age:protein related associations link to construction of age-modulated immune metabolic biological networks

- A: Prediction Rule Ensemble (PRE) modelling was performed in an iterative manner to select protein and clinical
- variable associations with ranked eGFR. At each iteration, only proteins not previously featured in a model were
- 657 considered. The rules found across all iterations were dominated by donor age terms.
- 658 B: Cumulative protein features identified at each iteration. Black line: all features identified by feature selection 659 approach. Blue line: features passing the secondary filter for predictive power and accuracy.
- 660 C: Shared Reactome pathway membership network analysis of filtered features. Nodes are colored by assigned
- 661 cluster, and the clusters are annotated according to the top three most enriched pathways within each cluster.
- 662

Cluster Label	Top 3 Shared Pathways
Immune Regulation and Complement Activation	Immune System
	Innate Immune System
	Regulation Of Complement Cascade
Protein Metabolism and Regulation	Metabolism Of Proteins
-	Post-translational Protein Modification
	Mitochondrial Translation Elongation
Metabolism	Metabolism
	Metabolism Of Amino Acids And Derivatives
	Pyruvate Metabolism And Citric Acid (TCA) Cycle
Apoptosis	Developmental Biology
	Role Of GTSE1 In G2/M Progression After G2
	Checkpoint
	Apoptosis
Striated Muscle Contraction	Striated Muscle Contraction

#### 663 Table 2: Shared Pathway Network Clusters

664 Proteins in Figure 4C were clustered by pathway membership, forming 4 major clusters and one minor cluster

665 (Striated Muscle Contraction). We assigned summary labels to each cluster based on the top 3 pathways with shared 666 membership in each cluster.



В



#### **Figure 5: Modelled associations between proteins and kidney transplant outcome change with donor age**

A: Ages at which the predicted probability of sub-median outcome is most different between the  $10^{\text{th}}$  percentile and

- 669  $90^{\text{th}}$  percentile of protein abundance. x axis: age at which difference is greatest (i.e. when protein has greatest 670 effect). y axis: greatest difference.
- 671 Proteins above x=0 are modelled as having a more negative association with outcome when the protein abundance is
- high, at that donor age. Proteins below x=0 are modelled to have a more positive association with outcome when
- 673 protein abundance is high, at that donor age.
- Proteins with absolute net difference >0.5 are labelled, as well as the selected proteins VTN, PREB, APOE andCST3.
- The inset graphs indicate how the prediction of sub-median outcome ("P(S-M outcome)"; y axes) changes with
- donor age (*x* axes) for labelled proteins. Black trace: prediction at median protein abundance. Purple trace:
- 678 prediction at 90<sup>th</sup> percentile of protein abundance. Orange trace: prediction at 10<sup>th</sup> percentile of protein abundance.
- The corresponding point on the main figure thus indicates the age at which the difference between orange and purple lines is greatest.
- 681 B: Summary of feature selection and modelling analysis



### Figure 6: Orthogonal validation confirms age-modulated immuno-metabolic proteins predict 12-month transplant outcomes

- A: Validation of models in test dataset. Models are plotted in order of decreasing Brier score (mean squared
- prediction error) *difference* between test and train data along the x axis. The lower two traces indicate the Brier score
- in train (purple) and test (green) data. The upper two traces indicate the AUC from the corresponding ROC analyses
- 688 in train (orange) and test (blue) data.
- B-E: Validation of four selected proteins. Left-Right: VTN, PREB, APOE, CST3.
- B: Final ROC curves and AUC values for models trained on each protein (and donor age) against test data. The
- 691 dotted line indicates the original performance against training data.
- 692 C: Change in the prediction of sub-median outcome ("P(S-M Outcome)"; y axes) with donor age (x axes) for each
- 693 protein. Black trace: prediction at median protein abundance. Purple trace: prediction at 90<sup>th</sup> percentile of protein
- abundance. Orange trace: prediction at 10<sup>th</sup> percentile of protein abundance. (These are the same as the inset graphs in Figure 5). The light grey and dark grey vertical lines, respectively, indicate the corresponding 'younger' and
- 696 'older' sampled ages for the western blots below.
- 697 D: Western blots comparing younger (age  $\leq$  49) and older (age  $\geq$  58) donors between Good Outcome (GO;
- $eGFR \ge 60$ ) and Suboptimal Outcome (SO;  $eGFR \le 40$ ) outcome tertiles. Top row: representative western blots
- 699 (n=5 per group) from comparison of younger donors. Middle row: representative western blots (n=5 per group) from
- 700 comparison of older donors. Bottom row: result values for all quantified samples relative to the GO mean. Error bars
- indicate ±1 standard deviation; the central wider bar indicates mean. Significance stars indicate t-test comparison p-
- 702 values (\*\*\*: < 0.001, \*: < 0.05).
- E: Predicted outcome for six paired Left (L) and Right (R) kidneys from three donors. x axes: recipient eGFR at 12
- months (i.e. actual outcome). y axes: predicted probability of sub-median outcome ("P(S-M Outcome)") using
- models trained on each protein with donor age. Vertical dotted line indicated median outcome (eGFR = 50).
- 706 Horizontal dotted line indicates P(Sub-Median Outcome) = 0.5